DDInter591 DDInter1631
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Doxapram {u} (Compound) resembles {v} (Compound) Loperamide
Doxapram {u} (Compound) resembles {v} (Compound) Minaprine
Doxapram {u} (Compound) binds {v} (Gene) KCNK3
Doxapram {u} (Compound) upregulates {v} (Gene) INPP1
Doxapram {u} (Compound) is included by {v} (Pharmacologic Class) Increased Medullary Respiratory Drive
Doxapram {u} (Compound) downregulates {v} (Gene) TRIB1
Doxapram {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Doxapram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dobutamine
Doxapram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylpropanolamine
Doxapram {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Doxapram (Compound) resembles Loperamide (Compound)
Doxapram (Compound) resembles Minaprine (Compound)
Doxapram (Compound) binds KCNK3 (Gene)
Doxapram (Compound) upregulates INPP1 (Gene)
Doxapram (Compound) is included by Increased Medullary Respiratory Drive (Pharmacologic Class)
Doxapram (Compound) downregulates TRIB1 (Gene)
Doxapram (Compound) causes Hyperhidrosis (Side Effect)
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine
Doxapram may lead to a major life threatening interaction when taken with Methylene blue